Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

Form 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (date of earliest event reported): December 4, 2007

SCOLR Pharma, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-31982   91-1689591
(State or other jurisdiction
of incorporation)		   (Commission File No.)   (I.R.S. Employer
Identification No.)

3625 132nd Avenue SE, Suite 400

Bellevue, WA 98006

(Address of principal executive offices)

(425) 373-0171

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

As used in this current report on Form 8-K, unless the context otherwise requires, the terms “we,” “us,” “the Company,” and “SCOLR Pharma” refer to SCOLR Pharma, Inc., a Delaware corporation.

 

Item 8.01. Other Events.

On December 4, 2007, SCOLR Pharma closed its previously reported registered direct offering of 2,781,100 shares of common stock and warrants to purchase 1,390,550 shares of common stock at a purchase price of $1.50 per unit. The five year warrants will be exercisable at an exercise price of $2.10 per share.

The securities in this transaction were offered by SCOLR pursuant to an effective shelf registration under the Securities Act of 1933, as amended.

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    SCOLR PHARMA, INC.
Dated: December 5, 2007     By:   /s/ Daniel O. Wilds
        Daniel O. Wilds
        President and Chief Executive Officer

 

3